In a fireside chat held on the floor of the New York Stock Exchange, Marc Hedrick, M.D., President and CEO of Plus Therapeutics, Inc., provided insights into the company’s groundbreaking targeted radio-therapeutics treatment for central nervous system (CNS) cancer. This innovative treatment utilizes the latest technology and has the potential to be effective against various types of brain and spinal cord cancers at any stage.
Plus Therapeutics, a clinical-stage pharmaceutical company based in Austin, Texas, is well-positioned to capitalize on the development of this novel treatment. With a hybrid virtual drug development model, the company has the ability to efficiently allocate resources, streamline operational processes, and accelerate product development.
The company’s headquarters in Austin, along with its additional laboratories and clean rooms in San Antonio, provide strategic advantages due to their proximity to renowned cancer institutions and researchers. This allows Plus Therapeutics to collaborate with experts and access funding opportunities through institutions like the Cancer Prevention and Research Institute of Texas (CPRIT).
Dr. Marc Hedrick, the President and CEO of Plus Therapeutics, brings a wealth of experience to the company. He has previously held executive leadership roles in the biopharmaceutical industry and has a background in surgery and regenerative bioengineering. Dr. Hedrick’s expertise will play a pivotal role in advancing the development of the targeted radio-therapeutics treatment.
The fireside chat offered valuable insights into Plus Therapeutics’ innovative approach to treating CNS cancer. With the potential to revolutionize cancer treatment, this novel therapy could offer hope to patients facing these challenging diagnoses.
For further information, please contact CorpGov.com at [email protected].
—
Definitions:
– Central nervous system cancer: Cancer that affects the brain and spinal cord.
– Targeted radio-therapeutics: Treatment that combines targeted therapy with radiation therapy to deliver radiation directly to cancer cells.
– Hybrid virtual drug development model: An approach that combines in-person and virtual collaboration to optimize drug development processes.
Sources:
– Healthcare Edge fireside chat with Marc Hedrick: [Source Link]
– Plus Therapeutics company information: [Source Link]
– Marc Hedrick biography: [Source Link]
